Analysis reveals SARDH as a key metabolic checkpoint in T-cell fate, suggesting targeting 1-C metabolism may improve cancer therapy outcomes.
Key Points
Elevated SARDH levels enhance T-cell function, promoting effective tumor control and potentially improving outcomes in cancer therapy.
Knocking down SARDH leads to increased sarcosine and diminished S-adenosylmethionine levels, indicating a shift in the T-cell metabolic balance.
Observational analysis using a single-cell transcriptional atlas across various cancers identified dysregulation of 1-C metabolism linked to T-cell dysfunction.
Targeting SARDH and understanding its metabolic pathways could provide new strategies for enhancing cancer immunotherapy effects.